Tekrardan Hoşgeldiniz
Cointime'ın Hizmet Şartları'ini kabul etmek ve Cointime'ın Gizlilik Politikası'inin sizin için geçerli olduğunu onaylamak için "Giriş "a tıklayın.
Cointime’a Katıl
Çoktan Hesabın Var mı?
Cointime'ın <a class="underline" href="#term-of-service">Hizmet Şartları</a>'ini kabul etmek ve Cointime'ın a class="underline" href="#privacy-policy">Gizlilik Politikası</a>'inin sizin için geçerli olduğunu onaylamak için "page.Sign up "a tıklayın.
Giriş Yap
Kayıt Ol
Posta kutunuz
Gelen kutunuzu kontrol edin
Giriş yapmak için emaildeki bağlantıya tıklayın.
Kayıt olmak için emaildeki bağlantıya tıklayın.
GluBio Therapeutics
company
About
GluBio Therapeutics engages in molecular glue-targeted protein degradation drug discovery.
Highlights
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- $50M
- Industries
- Biotechnology,Health Care,Medical
- Founded date
- Jan 1, 2021
- Operating Status
- Active
GluBio Therapeutics focuses on molecular glue-targeted protein degradation and provides a multi-dimensional protein degradation screening platform, an innovative target validation platform, a molecular glue rational design platform, and a proprietary library of highly active molecules.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$50M
GluBio Therapeutics has raised a total of
$50M
in funding over 2 rounds. Their latest funding was raised on
Feb 28, 2022 from a Series A round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Feb 28, 2022 | Series A | $50M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
GluBio Therapeutics is funded by 1 investors.
Lilly Asia Ventures
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Lilly Asia Ventures
|
— | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
